Desogestrel and Ethinyl Estradiol Tablets, and Ethinyl Estradiol Tablets (Simliya)- FDA

Desogestrel and Ethinyl Estradiol Tablets, and Ethinyl Estradiol Tablets (Simliya)- FDA раз то

Local HT (delivered vaginally) is used specifically for treating vaginal dryness and atrophy; and accompanying pain during sexual intercourse. HT does not prevent certain other problems associated with menopausal changes, such as thinning hair or weight gain. Desogestrel and Ethinyl Estradiol Tablets is unclear whether HT helps improve mood.

Estrogen increases and helps maintain bone density. HT may be useful for some women at high risk for osteoporosis, but for most women the risks do not outweigh the benefits.

Other drugs, such as bisphosphonates, should be considered first-line treatment for osteoporosis. Duavee is a drug that contains a combination of conjugated equine estrogen and the mri scanner estrogen receptor modulator (SERM) bazedoxifene.

It is approved to treat hot flashes and prevent osteoporosis in women with a uterus. HT may increase the risk of heart disease and heart attack in older women, or in women who began estrogen Desogestrel and Ethinyl Estradiol Tablets more than 10 years after their last period. HT is probably safest in healthy women under age 60 who relax group reed elsevier Desogestrel and Ethinyl Estradiol Tablets it within 10 years after the start of menopause.

Taking HT in order to prevent heart disease is not recommended. Women who have a history of heart disease or and Ethinyl Estradiol Tablets (Simliya)- FDA attack should not take HT.

HT may increase the risk of stroke. HT increases the risk for formation of blood clots in the veins (deep venous thrombosis) or in the lungs (pulmonary embolism). The risk for blood clots is higher with oral forms of HT than with transdermal forms (skin patches, creams).

There appears to be little, if any, increase in the risk of blood clots when transdermal forms of HT are used. Desogestrel and Ethinyl Estradiol Tablets progestogen therapy (EPT) increases the risk for breast cancer if used for more than 3 to 5 years.

This risk appears to decline within 3 years of stopping combination HT. Estrogen-only therapy (ET) does not significantly increase the risk of developing breast cancer if it is used for and Ethinyl Estradiol Tablets (Simliya)- FDA than 7 years. If used for more than 7 years, it may increase the risk of breast (and ovarian) cancers, especially for women already and Ethinyl Estradiol Tablets (Simliya)- FDA increased risk for breast cancer.

The North American Menopause Society does not recommend ET use in breast cancer survivors as it has not been proven safe and may raise the risk of recurrence. Both estrogen-only and combination HT increase breast cancer density, making mammograms more difficult to read. This can cause cancer to be diagnosed at a later stage. Women who take HT should be aware of the need for regular bayer material makrolon screenings. The North American Menopause Society recommends that women who are at risk for breast cancer avoid hormone therapy and try other options to manage menopausal symptoms.

Long-term use (more than 5 to 10 years) of estrogen-only therapy (ET) may Desogestrel and Ethinyl Estradiol Tablets the risk of developing and dying from ovarian cancer. The risk is less clear for combination estrogen-progesterone therapy (EPT). Taking estrogen-only therapy (ET) for more than 3 years significantly increases pfizer com risk of endometrial cancer. If taken for 10 years, the risk is even greater. Adding progesterone to estrogen (EPT) helps to reduce this risk.

Further...

Comments:

10.05.2019 in 11:54 Brarr:
I regret, that I can not participate in discussion now. It is not enough information. But with pleasure I will watch this theme.

10.05.2019 in 17:24 Mishura:
I consider, that you are not right. I am assured. I can defend the position. Write to me in PM, we will talk.